ArticleOncoTargets and therapy2016
Expression and clinical significance of Nectin-4 in hepatocellular carcinoma.
Article in OncoTargets and therapy, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Prognostic value of nectin-4 in human cancers: A meta-analysis.Frontiers in oncology · 2023Pooled it
- Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development.British journal of cancer · 2023Trial
- Nectin-4 expression in clear cell renal cell carcinoma.Scientific reports · 2026Article
- Double metastatic cancer with lung and urothelial carcinoma responding to enfortumab vedotin: a case report and review of the literature.Journal of medical case reports · 2025Review
- Nectin-4 expression patterns and therapeutics in oncology.Cancer letters · 2025Review
- Nectin4-targeted molecular imaging in solid tumors: Current status and future perspectives.View (Beijing, China) · 2025Article
- Assessing the expression of Nectin-4 in solid tumors by immunohistochemistry - what do we know?Histology and histopathology · 2025Review
- Laryngeal Squamous Cell Carcinoma Is Characterized by a Stronger Expression of Nectin-4 Compared to Nectin-2.Current issues in molecular biology · 2025Article
- Article
- Therapeutic prospects of nectin-4 in cancer: applications and value.Frontiers in oncology · 2024Review
- A Specificity Protein 1 assists the Progression of the Papillary Thyroid Cell Line by InitiatingEndocrine, metabolic & immune disorders drug targets · 2024Article
- Metastatic Bladder Cancer Expression and Subcellular Localization of Nectin-4 and Trop-2 in Variant Histology: A Rapid Autopsy Study.Clinical genitourinary cancer · 2023Article
- Anti-tumor activity of a recombinant measles virus against canine lung cancer cells.Scientific reports · 2023Article
- Review
- Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E-based Antibody-Drug Conjugate for Treatment of Nectin-4-expressing Cancers.Molecular cancer therapeutics · 2023Article
- Production and characterization of single-chain variable fragment antibodies targeting the breast cancer tumor marker nectin-4.Frontiers in immunology · 2023Article
- Expression of nectin-4 in papillary renal cell carcinoma.Discover oncology · 2022Article
- Nectin-4 promotes osteosarcoma progression and metastasis through activating PI3K/AKT/NF-κB signaling by down-regulation of miR-520c-3p.Cancer cell international · 2022Article
- High expression of nectin-1 indicates a poor prognosis and promotes metastasis in hepatocellular carcinoma.Frontiers in oncology · 2022Article
- Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.Expert opinion on biological therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNectin-4 is a member of the Nectin family of four Ca(+)-independent immunoglobulin-like cell adhesion molecules and implicated in cell adhesion, movement, proliferation, differentiation, polarization, and survival. The aberrant expression of Nectin-4 has been found in a variety of tumors; however, its expression in hepatocellular carcinoma (HCC) is still poorly understood. This study was to investigate the expression of Nectin-4 and its clinical significance in the patients with HCC.
methodsThe expression of Nectin-4 was assessed at mRNA and protein levels by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blotting assays in 20 HCC specimens and adjacent non-tumor live tissues. Furthermore, the clinical significance of Nectin-4 in 87 cases of HCC was confirmed by immunohistochemistry.
resultsThe mRNA and protein levels of Nectin-4 were higher in HCC tumor tissues than in the matched non-tumor tissues. Nectin-4 was located in the cytoplasm of tumor cells and over-expressed in 67.82% (59/87) HCC tissues by immunohistochemical staining. Positive Nectin-4 expression was significantly correlated with tumor size (P=0.029), status of metastasis (P=0.023), vascular invasion (P=0.018) and tumor-node-metastasis stage (P=0.003). In addition, Kaplan-Meier survival analysis indicated that positive Nectin-4 expression was associated with worse recurrence-free survival (RFS) and overall survival (OS) (P=0.006 and P=0.005, respectively). In multivariate analysis, Nectin-4 was an independent prognostic factor for RFS and OS in the patients with HCC.
conclusionNectin-4 is upregulated in HCC and may be a novel prognostic biomarker for the patients after surgical resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.